Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  4Sc AG    VSC   DE000A14KL72

4SC AG (VSC)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/23/2017 Date
4.894(c) 4.561(c) 4.571(c) 4.6(c) 4.679 Last
8 984 53 721 26 997 12 979 2 545 Volume
-1.53% -6.80% +0.22% +0.63% +1.72% Change
More quotes
Financials (€)
Sales 2017 4,70 M
EBIT 2017 -13,1 M
Net income 2017 -11,1 M
Finance 2017 39,5 M
Yield 2017 -
Sales 2018 4,95 M
EBIT 2018 -14,5 M
Net income 2018 -11,1 M
Finance 2018 26,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 21,6x
EV / Sales2018 23,1x
Capitalization 141 M
More Financials
Company
4SC AG engages in the development of small molecule drugs that targets cancer through epigenetic mechanisms.It also involves in the preclinical and clinical development of its products.Its assets are resminostat, 4SC-202, and 4SC-208.The company was founded by Ulrich Dauer, Daniel Vitt, Stefan... 
More about the company
Surperformance© ratings of 4Sc AG
Trading Rating : - Investor Rating :
More Ratings
Latest news on 4SC AG
11/07 4SC AG : Notification and public disclosure of transactions by persons
11/06 4SC : First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melano..
11/02 4SC AG : 10 upcoming conferences and investor events
10/26 4SC : provides Q3 and 9M 2017 update
10/10 4SC AG : Resminostat demonstrates potential to significantly alleviate itching i..
09/13 4SC : Phase I study of 4SC's resminostat indicates efficacy in biliary tract can..
08/31 4SC : to present at upcoming scientific conferences
08/10 4SC : provides Q2 and 6M 2017 update
08/03 4SC AG : Conference call to be hosted on 10 August 2017 to present the half-year..
08/01 4SC : was granted a fundamental composition of matter patent for 4SC-208 for the..
More news
Sector news : Biotechnology & Medical Research - NEC
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 4SC AG Presents at The German Equity Forum 2016
Chart 4SC AG
Duration : Period :
4Sc AG Technical Analysis Chart | VSC | DE000A14KL72 | 4-Traders
Technical analysis trends 4SC AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,50 €
Spread / Average Target -24%
EPS Revisions
Managers
NameTitle
Jason Loveridge Chairman-Management Board & CEO
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Roland Baumgartner Chief Scientific Officer
Manfred Rüdiger Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
4SC AG90.87%167
CELLTRION, INC.--.--%24 331
IQVIA HOLDINGS INC37.23%21 966
INCYTE CORPORATION-1.32%20 893
LONZA GROUP62.21%19 860
ALNYLAM PHARMACEUTICALS, INC.252.59%13 012